GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (FRA:2SX) » Definitions » Research & Development

scPharmaceuticals (FRA:2SX) Research & Development : €11.48 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is scPharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. scPharmaceuticals's Research & Development for the three months ended in Mar. 2024 was €2.51 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €11.48 Mil.

scPharmaceuticals Research & Development Historical Data

The historical data trend for scPharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

scPharmaceuticals Research & Development Chart

scPharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only 22.17 14.92 14.20 14.66 10.83

scPharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.98 2.71 3.21 3.06 2.51

scPharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

scPharmaceuticals  (FRA:2SX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

scPharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of scPharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

scPharmaceuticals (FRA:2SX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (FRA:2SX) » Definitions » Research & Development
Comparable Companies
ENTA MCRB RENB AEON INZY IVVD GRTS DNTH CBUS PSTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
SCPH:USA
Address
2400 District Avenue, Suite 310, Burlington, MA, USA, 01803
Website
https://www.scpharmaceuticals.com
scPharmaceuticals Inc is a pharmaceutical company. Its pipeline includes products in various stages of clinical and non-clinical development. It focuses on pharmaceutical products in the cardiovascular and infectious disease therapeutic areas. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.

scPharmaceuticals (FRA:2SX) Headlines

No Headlines